MedTrace Logo

Prevention of Chemotherapy-Induced Ovarian Failure With Goserelin in Premenopausal Lymphoma Patients

NCT04536467 · Status: ENROLLING_BY_INVITATION · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 80

Last updated 2024-03-19

No results posted yet for this study

Summary

To Prevent Chemotherapy Induced Ovarian Failure with the gonadotropin-releasing hormone Agonist Goserelin in Young female Lymphoma Cancer patients Receiving Chemotherapy

Conditions

  • Premature Ovarian Failure

Interventions

DRUG

Goserelin

chemotherapy+goserelin

DRUG

Chemotherapy

standard chemotherapy

Sponsors & Collaborators

  • Beni-Suef University

    lead OTHER

Principal Investigators

  • Ahmed Abdullah Elberry Elberry, MD · Assistant Professor of Clinical Pharmacology, Beni-Suef University

  • Raghda Roshdy Sayed Hussein, MD · Lecturer of Clinical pharmacy, Beni-Suef University

  • ahmed hassan shaaban · Lecturer of Clinical Oncology, Beni-Suef University

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
17 Years
Max Age
40 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-03-01
Primary Completion
2020-12-01
Completion
2024-11-01

Countries

  • Egypt

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04536467 on ClinicalTrials.gov